GENMAB A/S -SP ADR (GMAB) Forecast, Price Target & Analyst Ratings
NASDAQ:GMAB • US3723032062
27.06 USD
-0.42 (-1.53%)
At close: Mar 6, 2026
26.51 USD
-0.55 (-2.03%)
Pre-Market: 3/9/2026, 5:21:55 AM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GENMAB A/S -SP ADR (GMAB).
Forecast Snapshot
Consensus Price Target
$135.67
+ 401.37% Upside
Next Earnings Forecast
Release DateMay 7, 2026
PeriodQ1 / 2026
EPS Estimate$0.25
Revenue Estimate928.95M
ChartMill Buy Consensus
73.85%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$135.67
Upside
+ 401.37%
From current price of $27.06 to mean target of $135.67, Based on 26 analyst forecasts
Low
$21.08
Median
$126.01
High
$263.69
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
26 analysts have analysed GMAB and the average price target is 95.18 USD. This implies a price increase of 251.75% is expected in the next year compared to the current price of 27.06.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
73.85%
GMAB was analyzed by 26 analysts. The buy percentage consensus is at 74. So analysts seem to be have mildly positive about GMAB.
In the previous month the buy percentage consensus was at a similar level.
GMAB was analyzed by 26 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-02 | Wells Fargo | Initiate | Overweight |
| 2026-02-23 | Guggenheim | Maintains | Buy -> Buy |
| 2026-02-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-17 | Jefferies | Reiterate | Buy |
| 2026-02-16 | Morgan Stanley | Reiterate | Equal-Weight |
| 2026-01-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-01-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-07 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-10-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-02 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-09-24 | Guggenheim | Upgrade | Neutral -> Buy |
| 2025-09-23 | Guggenheim | Upgrade | Neutral -> Buy |
| 2025-08-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-08 | Truist Securities | Maintains | Buy -> Buy |
| 2025-04-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-11 | William Blair | Upgrade | Market Perform -> Outperform |
| 2025-03-11 | Truist Securities | Maintains | Buy -> Buy |
| 2025-02-13 | Leerink Partners | Upgrade | Market Perform -> Outperform |
| 2025-01-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-08 | BMO Capital | Reiterate | Outperform -> Outperform |
| 2024-10-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 7, 2026
PeriodQ1 / 2026
EPS Estimate$0.25
Revenue Estimate928.95M
Revenue Q2Q29.92%
EPS Q2Q-19.20%
Number of Analysts9
Next Earnings Revisions
Revenue (1 Month)
0.88%
Revenue (3 Months)
0.88%
EPS (1 Month)
-33.10%
EPS (3 Months)
-33.10%
Next Earnings Summary
GMAB is expected to report earnings on 5/7/2026. The consensus EPS estimate for the next earnings is 0.25 USD and the consensus revenue estimate is 928.95M USD.
The next earnings revenue estimate has been revised upward by 0.88% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.391B 16.63% | 3.122B 30.57% | 3.72B 19.15% | 4.382B 17.80% | 5.033B 14.86% | 5.94B 18.02% | 6.497B 9.38% | 6.781B 4.37% | 6.784B 0.04% | 6.715B -1.02% | 7.175B 6.85% | |
| EBITDA YoY % growth | 815.128M -13.49% | 1.087B 33.30% | 1.339B 23.23% | 1.295B -3.29% | 1.699B 31.20% | 2.24B 31.84% | 2.523B 12.63% | 1.657B -34.32% | 1.996B 20.46% | 1.75B -12.32% | 2.249B 28.51% | |
| EBIT YoY % growth | 772.311M -13.33% | 1.027B 32.94% | 1.268B 23.50% | 1.269B 0.08% | 1.614B 27.19% | 2.214B 37.17% | 2.116B -4.43% | 2.178B 2.93% | 2.16B -0.83% | 2.145B -0.69% | 2.376B 10.77% | |
| Operating Margin | 32.30% | 32.89% | 34.09% | 28.96% | 32.07% | 37.27% | 32.57% | 32.12% | 31.84% | 31.94% | 33.11% | |
| EPS YoY % growth | 0.99 -17.57% | 1.79 82.09% | 1.75 -2.61% | 1.48 -15.07% | 1.93 30.22% | 2.87 48.37% | 2.69 -6.18% | 2.80 4.04% | 3.06 9.35% | 3.05 -0.48% | 3.41 11.97% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | 0.25 -19.20% | 0.35 -37.29% | 0.61 -8.34% | 0.58 167.05% |
| Revenue Q2Q % growth | 928.95M 29.92% | 1.125B 21.62% | 1.178B 15.26% | 1.186B 12.10% |
| EBITDA Q2Q % growth | 246.1M 20.64% | 290.45M -25.91% | 664.45M 30.54% | N/A |
| EBIT Q2Q % growth | 177.12M -5.79% | 295.5M -17.92% | 523.54M 14.06% | 523.81M 115.56% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
17.95%
EPS Next 5 Year
9.88%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
17.06%
Revenue Next 5 Year
12.86%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
19.49%
EBIT Next 5 Year
4.76%
GENMAB A/S -SP ADR / GMAB Forecast FAQ
What is the average price target for GENMAB A/S -SP ADR (GMAB) stock?
26 analysts have analysed GMAB and the average price target is 95.18 USD. This implies a price increase of 251.75% is expected in the next year compared to the current price of 27.06.
What is the next earnings date for GMAB stock?
GENMAB A/S -SP ADR (GMAB) will report earnings on 2026-05-07.
Can you provide the consensus estimates for GENMAB A/S -SP ADR next earnings?
The consensus EPS estimate for the next earnings of GENMAB A/S -SP ADR (GMAB) is 0.25 USD and the consensus revenue estimate is 928.95M USD.
What is the consensus rating for GENMAB A/S -SP ADR (GMAB) stock?
The consensus rating for GENMAB A/S -SP ADR (GMAB) is 73.8462 / 100 . This indicates that analysts generally have a positive outlook on the stock.